Limes Schlosskliniken AG (LIK) AI Stock Analysis

• Market Cap: €118.80M
• Dividend Yield: N/A
• Average Volume (3M): 32.00
• Price to Earnings (P/E): 25.3
• Beta (1Y): <0.01
• Revenue Growth: 0.21%
• EPS Growth: 7.53%
• Country: DE
• Employees: 210
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Care Facilities
• EPS (TTM): 11.30
• Shares Outstanding: 300,000
• 10 Day Avg. Volume: 38
• 30 Day Avg. Volume: 32
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €438.00
• Price Target Upside: 10.61% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: €438.00 ▲(10.61% Upside)

Limes Schlosskliniken AG's overall stock score is driven by its strong financial performance, which is the most significant factor. The technical analysis indicates a bullish trend, but with potential overbought conditions. The valuation is relatively high, which may limit further upside. The absence of earnings call data and corporate events means these factors do not influence the score.

Limes Schlosskliniken AG Business Overview & Revenue Model

Company Description

LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of GMF Capital Gmbh.

How the Company Makes Money

Limes Schlosskliniken AG makes money primarily through the provision of healthcare services at its mental health clinics. The company's revenue model is based on patient fees, which are often covered by health insurance providers. LIK charges for a range of services including consultations, therapy sessions, inpatient care, and specialized treatment programs. Additionally, the company may generate income through partnerships with healthcare providers and insurance companies, which help facilitate patient access to their services. The quality of care, reputation of their clinics, and strategic locations contribute significantly to attracting patients and generating revenue.

Limes Schlosskliniken AG Financial Statement Overview

Summary

Limes Schlosskliniken AG exhibits strong financial health with robust revenue and profit growth, efficient operations, and a stable balance sheet. The company demonstrates effective cash flow management, enhancing liquidity. While the debt level is manageable, continued focus on maintaining operational efficiency and prudent capital investment will be essential to sustain growth and mitigate risks.

Income Statement

Limes Schlosskliniken AG has demonstrated a strong revenue growth trajectory, increasing its total revenue annually from 2019 to 2024. The gross profit margin has been consistently high, indicating efficient cost management. The net profit margin has improved significantly, reflecting enhanced profitability. EBIT and EBITDA margins are robust, showcasing operational efficiency. However, a slight dip in EBIT in 2024 suggests some pressure on earnings.

Balance Sheet

The balance sheet reveals a solid equity position with an increasing stockholders' equity from 2019 to 2024. The company maintains a manageable debt-to-equity ratio, indicating prudent leverage levels. The equity ratio signifies a strong financial base with a significant portion of assets funded by equity. Despite a slight increase in total debt, the company's equity growth offsets potential risks, sustaining a stable financial structure.

Cash Flow

Cash flow analysis shows a positive trend in operating cash flow, suggesting healthy cash generation from core operations. The free cash flow has recovered from negative values in earlier years to positive in recent periods, reflecting improved cash management. The operating cash flow to net income ratio supports stability, although capital expenditures remain significant, potentially impacting future liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.45M	37.17M	28.81M	23.43M	11.02M
Gross Profit	34.50M	16.23M	10.82M	8.37M	2.80M
EBITDA	7.05M	7.67M	8.65M	6.02M	837.74K
Net Income	3.11M	3.40M	4.20M	3.94M	-694.42K
Balance Sheet
Total Assets	38.56M	33.25M	26.65M	18.44M	11.79M
Cash, Cash Equivalents and Short-Term Investments	10.88M	8.52M	10.93M	2.48M	2.68M
Total Debt	10.48M	10.09M	9.04M	4.33M	3.85M
Total Liabilities	18.72M	16.61M	15.45M	12.13M	9.11M
Stockholders Equity	18.33M	15.13M	11.10M	6.31M	2.68M
Cash Flow
Free Cash Flow	2.48M	-3.51M	6.35M	-1.83M	-1.00M
Operating Cash Flow	7.46M	6.29M	7.70M	4.55M	759.00K
Investing Cash Flow	-4.96M	-9.79M	-1.31M	-6.38M	-1.83M
Financing Cash Flow	-159.15K	1.09M	2.04M	1.62M	2.53M

Limes Schlosskliniken AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 396.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:LIK, the sentiment is Positive. The current price of 396 is above the 20-day moving average (MA) of 355.80, above the 50-day MA of 369.28, and above the 200-day MA of 330.75, indicating a bullish trend. The MACD of 1.94 indicates Negative momentum. The RSI at 65.10 is Neutral, neither overbought nor oversold. The STOCH value of 82.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:LIK.

Limes Schlosskliniken AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LIK	69 Neutral	€118.80M	25.26	23.66%	―	0.21%	7.53%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
0NDG	―	€141.55M	4.00	15.78%	―	―	―
MAK	43 Neutral	€23.70M	―		―	11.43%	7.72%
EIF	―	€5.82M	1.90	29.97%	―	―	―
JTH0	―	€23.40M	11.43		―	―	―
M12	69 Neutral	€249.17M	15.45	14.61%	3.69%	7.23%	58.37%